Linked Life Data

12649124

Source:http://linkedlifedata.com/resource/pubmed/id/12649124

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12649124rdf:typepubmed:Citationlld:pubmed
pubmed-article:12649124lifeskim:mentionsumls-concept:C0021759lld:lifeskim
pubmed-article:12649124lifeskim:mentionsumls-concept:C0003241lld:lifeskim
pubmed-article:12649124lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:12649124lifeskim:mentionsumls-concept:C1960048lld:lifeskim
pubmed-article:12649124lifeskim:mentionsumls-concept:C0031928lld:lifeskim
pubmed-article:12649124pubmed:issue12lld:pubmed
pubmed-article:12649124pubmed:dateCreated2003-6-10lld:pubmed
pubmed-article:12649124pubmed:abstractTextAntagonizing the effect of interleukin (IL)-5 is a potential new treatment strategy in allergic disorders. We evaluated the safety, biological activity, and pharmacokinetics of SCH55700, a humanized anti-human IL-5 antibody, in subjects with severe persistent asthma treated with oral or high doses of inhaled steroids. In a double-blind, randomized, multicenter trial, a rising single dose of SCH55700 (0.03 mg/kg [n = 2], 0.1 mg/kg [n = 4], 0.3 mg/kg [n = 6], or 1.0 mg/kg [n = 12]) or placebo (n = 8) was administered intravenously. SCH55700 dose dependently reduced circulating eosinophil counts. At a dose of 1.0 mg/kg, the decrease remained significant up to Day 30 [(0.07 +/- 0.01) x 10(9)/L versus (0.23 +/- 0.04) x 10(9)/L at baseline] (mean +/- SEM) (p = 0.05). After administration of SCH55700 at 0.3 and 1.0 mg/kg, a trend toward improvement in baseline FEV1 was observed, which reached significance 24 hours after the 0.3-mg/kg dose (p = 0.019 versus placebo). No significant changes occurred in other clinical indices of disease activity. Adverse events were not different between active treatment and placebo. We conclude that SCH55700 is a biologically active anti-human IL-5 antibody that can be safely used in severe steroid-treated asthma. Its therapeutic potential needs to be addressed in specifically designed efficacy trials.lld:pubmed
pubmed-article:12649124pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649124pubmed:languageenglld:pubmed
pubmed-article:12649124pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649124pubmed:citationSubsetAIMlld:pubmed
pubmed-article:12649124pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649124pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649124pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649124pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12649124pubmed:statusMEDLINElld:pubmed
pubmed-article:12649124pubmed:monthJunlld:pubmed
pubmed-article:12649124pubmed:issn1073-449Xlld:pubmed
pubmed-article:12649124pubmed:authorpubmed-author:PostmaDirkje...lld:pubmed
pubmed-article:12649124pubmed:authorpubmed-author:KerstjensHuib...lld:pubmed
pubmed-article:12649124pubmed:authorpubmed-author:WoodcockAshle...lld:pubmed
pubmed-article:12649124pubmed:authorpubmed-author:PauwelsRomain...lld:pubmed
pubmed-article:12649124pubmed:authorpubmed-author:KipsJohan CJClld:pubmed
pubmed-article:12649124pubmed:authorpubmed-author:LangleyStephe...lld:pubmed
pubmed-article:12649124pubmed:authorpubmed-author:CussFrancisFlld:pubmed
pubmed-article:12649124pubmed:authorpubmed-author:O'ConnorBrian...lld:pubmed
pubmed-article:12649124pubmed:authorpubmed-author:DanzigMelMlld:pubmed
pubmed-article:12649124pubmed:issnTypePrintlld:pubmed
pubmed-article:12649124pubmed:day15lld:pubmed
pubmed-article:12649124pubmed:volume167lld:pubmed
pubmed-article:12649124pubmed:ownerNLMlld:pubmed
pubmed-article:12649124pubmed:authorsCompleteYlld:pubmed
pubmed-article:12649124pubmed:pagination1655-9lld:pubmed
pubmed-article:12649124pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:meshHeadingpubmed-meshheading:12649124...lld:pubmed
pubmed-article:12649124pubmed:year2003lld:pubmed
pubmed-article:12649124pubmed:articleTitleEffect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study.lld:pubmed
pubmed-article:12649124pubmed:affiliationDepartment of Respiratory Diseases, Ghent University Hospital, De Pintelaan 185, B 9000 Ghent, Belgium. johan.kips@rug.ac.belld:pubmed
pubmed-article:12649124pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12649124pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12649124pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:12649124pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12649124lld:pubmed